Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

8.220 -0.320 (-3.75%)

Streaming Delayed Price Updated: 10:47 AM EDT, Jul 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	98,740
Open	8.540
Bid (Size)	8.210 (100)
Ask (Size)	8.230 (300)
Prev. Close	8.540
Today's Range	8.130 - 8.540
52wk Range	6.055 - 14.51
Shares Outstanding	63,500,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗

June 05, 2026

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where...

Via MarketBeat

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

June 04, 2026

From Arvinas Inc.

Via GlobeNewswire

Performance

YTD	-28.3%	-28.3%
1 Month	+14.0%	+14.0%
3 Month	-26.4%	-26.4%
6 Month	-32.5%	-32.5%
1 Year	-0.1%	-0.1%

More News

Arvinas to Present at Jefferies Global Healthcare Conference

May 29, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas Employees Give Back During Company-wide Impact Day

May 18, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss ↗

May 12, 2026

Via Chartmill

Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates ↗

February 24, 2026

Via Chartmill

These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗

May 13, 2026

Via Benzinga

Arvinas Q1 Earnings Call Highlights ↗

May 12, 2026

Via MarketBeat

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

May 05, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

May 01, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

March 18, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

March 11, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Via The Motley Fool

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 24, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

February 23, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 17, 2026

From Arvinas Inc.

Via GlobeNewswire

ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff ↗

February 12, 2026

Via Stocktwits

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

February 12, 2026

From Arvinas Inc.

Via GlobeNewswire

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

December 06, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

November 26, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

November 24, 2025

From Arvinas Inc.

Via GlobeNewswire

Top movers in Tuesday's session ↗

November 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 18, 2025

Via Benzinga

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?

Yes, Arvinas, Inc. - Common Stock is publicly traded.

What exchange does Arvinas, Inc. - Common Stock trade on?

Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arvinas, Inc. - Common Stock?

The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market

What is the current price of Arvinas, Inc. - Common Stock?

The current price of Arvinas, Inc. - Common Stock is 8.220

When was Arvinas, Inc. - Common Stock last traded?

The last trade of Arvinas, Inc. - Common Stock was at 07/10/26 10:47 AM ET

What is the market capitalization of Arvinas, Inc. - Common Stock?

The market capitalization of Arvinas, Inc. - Common Stock is 521.97M

How many shares of Arvinas, Inc. - Common Stock are outstanding?

Arvinas, Inc. - Common Stock has 522M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.